[1]
N. S. B. Rawson, “Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand”, J Popl Ther Clin Pharmacol, vol. 27, no. 2, pp. e58-e67, Jun. 2020.